Baird raised the firm’s price target on Boston Scientific (BSX) to $123 from $117 and keeps an Outperform rating on the shares. The firm updated its guidance following its beat and raise Q2 results which increased conviction as a best-in-class growth stock. Boston Scientific remains a top idea.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target raised to $135 from $130 at UBS
- Boston Scientific price target raised to $124 from $118 at Wells Fargo
- Boston Scientific price target raised to $133 from $125 at Barclays
- Boston Scientific Reports Strong Q2 2025 Results
- Boston Scientific Reports Strong Q2 Growth Amid Challenges